Skip to main content
. 2019 Jan 8;37(6):481–489. doi: 10.1200/JCO.18.00766

FIG 3.

FIG 3.

Prevalence and spectrum of 9p24.1 genetic alterations and association of residual disomy with 9p24.1 genetic categories. (A) Prevalence of 9p24.1 genetic alterations in evaluated diffuse large B-cell lymphomas (DLBCLs). (B) Spectrum of 9p24.1 alterations in evaluated DLBCLs. Each patient is classified by the highest observed level of 9p24.1 alteration in tumor cells: polysomy, copy gain, amplification (Ampl), or rearrangement (Rearr). Individual patients are visualized as columns on the x-axis. Percentages of tumor cells with monosomy/relative copy loss (gray), disomy (black), polysomy (light red), copy gain (medium red), amplification (dark red), and rearrangement (brown) are depicted on the y-axis. In cases with evaluable 9p24.1 status and PD-L1 immunohistochemistry (n = 46), programmed death ligand 1 (PD-L1) expression (H-score) on PAX5-positive malignant B cells is indicated below the x-axis (membranous PD-L1 in red, cytoplasmic PD-L1 in blue). (C) Percentage of tumor cells with residual 9p24.1 disomy in DLBCLs classified by 9p24.1 genetic categories (P < .001 from ordinary one-way analysis of variance of unpaired t test data). Coampl, coamplification; PD-L2, programmed death ligand 2.